Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 25 | SFEBES2011 | Next issue

Society for Endocrinology BES 2011

Poster Presentations


Influence of age and gender on expression of primary hyperparathyroidism
Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Vitamin D insufficiency in hyperparathyroidism
1University of Hull, Hull, UK; 2Hull and East Yorksire Hospitals NHS Trust, Hull, UK.
Thyrostimulin expression and signalling in the skeleton
1Molecular Endocrinology Group, Department of Medicine and Medical Research Council Clinical Sciences Centre, Imperial College London, Hammersmith Hospital, London W12 0NN, UK; 2Oral Growth and Development, Institute of Dentistry, Bart’s and London School of Medicine, Queen Mary, University of London, London E1 1BB, UK; 3Department of Endocrinology and Metabolism, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.
Serum 25-OH-vitamin D levels in thalassaemia major
The Whittington Hospital NHS Trust, London, UK.
Bone turnover markers in patients on aminobisphosphonate therapy for osteoporosis
1Department of Endocrinology, St Vincent’s Hospital, Dublin, Ireland; 2Metabolism Laboratory, St Vincent’s Hospital, Dublin, Ireland.
Lithium-induced hypercalcaemia: 'past, present, and future'
Southampton General Hospital, Southampton, UK.
A gene causing autosomal dominant kyphoscoliosis in an N-ethyl-N-nitrosourea (ENU) mutagenised mouse model is located on a 5 Mb interval on mouse chromosome 4 band A3
1University of Oxford, Oxford, Oxfordshire, UK; 2MRC Harwell, Harwell, Oxfordshire, UK; 3University of Sheffield, Sheffield, UK; 4University of Queensland, Queensland, Australia.
Parathyroid hormone concentrations in proton pump inhibitor induced hypomagnesaemia
Department of Endocrinology, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham, Birmingham, UK.
The long-term safety and efficacy of zoledronic acid in the treatment of osteoporosis: a 3-year, randomized extension to the HORIZON-pivotal fracture trial (PFT)
1University of Sheffield, Sheffield, UK; 2University of Auckland, Auckland, New Zealand; 3University of Pittsburgh, Pittsburgh, Pennsylvania, USA; 4Katholieke Universiteit Leuven, Leuven, Belgium; 5Helen Hayes Hospital, West Haverstraw, New York, USA; 6Chinese University of Hong Kong, Hong Kong, China; 7Semmelweis University Medical School, Budapest, Hungary; 8Centro Tratamiento Integral Endocrinología, Buenos Aires, Argentina; 9San Francisco Coordinating Center, San Francisco, California, USA; 10University of California, San Francisco, California, USA; 11Novartis Pharmaceuticals, East Hanover, New Jersy, USA.
Cervical cord compression in a patient with Paget's disease and primary hyperparathyroidism: a diagnostic challenge
1Department of Endocrinology, Royal Preston Hospital, Preston, Lancashire, UK; 2Department of Neurosurgery, Royal Preston Hospital, Preston, Lancashire, UK.
Immobility: a rare cause of hypercalcaemia
1Diabetes and Endocrinology Unit, Countess of Chester Hospital NHS Foundation Trust, Chester, UK; 2Department of Blood Sciences, Countess of Chester Hospital NHS Foundation Trust, Chester, UK.
Ablation of AMP-activated protein kinase (AMPK) [alpha]1 catalytic subunit in mice leads to decreased bone loss after ovariectomy and impaired bone response to intermittent PTH treatment
1Veterinary Basic Sciences, Royal Veterinary College, London, UK; 2INSERM U567, Paris, France; 3Endocrinology, Queen Mary University of London, London, UK.
Management of primary hyperparathyroidism
Walsall Manor Hospital, Walsall, West Midlands, UK.